Levemir Flexpen (Insulin detemir)

This medication, commonly used by people with diabetes who are on multiple daily injections of insulin, will no longer be available due to various challenges faced by the manufacturer, Novo Nordisk.

When Will Levemir Be Discontinued?

• Levemir FlexPen: Supply disruption starting mid-January 2024, discontinuation on April 1, 2024.
• Levemir Vials: Discontinuation on December 31, 2024.
• Reason: Supply chain issues leading to imminent shortages.

Why Is Levemir Being Discontinued?

• Global Manufacturing Constraints: Challenges in production.
• Formulary Losses: Impacting patient access.
• Availability of Alternatives: Presence of other treatment options.
• Context: Announcement follows Novo Nordisk’s plan to cut insulin prices by up to 75% from January 1, 2024, and Eli Lilly’s cap on insulin costs at $35 per month.

Levemir vs. Tresiba: What’s the Difference?

• Levemir (Insulin Detemir): Approved in 2005, long-acting insulin, effective for up to 24 hours, twice-daily dosing, approved for pregnancy.
• Tresiba (Insulin Degludec): Approved in 2015, long-acting insulin, effective for 42 hours, once-daily dosing, fewer severe hypoglycemic episodes, flexible dosing schedule.